Comparative Pharmacology
Head-to-head clinical analysis: FLUORINE F 18 versus MPI DMSA KIDNEY REAGENT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUORINE F 18 versus MPI DMSA KIDNEY REAGENT.
FLUORINE F-18 vs MPI DMSA KIDNEY REAGENT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluorine-18 decays by positron emission, and the emitted positron annihilates with an electron to produce two 511 keV gamma photons. When incorporated into radiopharmaceuticals such as fludeoxyglucose F-18, it accumulates in metabolically active tissues, enabling PET imaging.
DMSA (dimercaptosuccinic acid) labeled with technetium-99m binds to renal cortex, particularly proximal tubular cells, allowing scintigraphic imaging of functional renal parenchyma. Uptake correlates with renal blood flow and tubular function.
2-10 mCi (74-370 MBq) intravenous bolus, single administration for PET imaging.
Adults: 74-185 MBq (2-5 mCi) intravenously, single dose for renal imaging.
None Documented
None Documented
Physiological half-life is 109.7 minutes (1.83 hours) for fluorine-18 decay by positron emission, with a physical half-life of 109.7 minutes. The biological half-life is dependent on the radiolabeled compound; for [18F]FDG, the effective half-life is approximately 3-4 hours.
Initial whole-body half-life of dimer captosuccinic acid (DMSA) is 1.1 hours; terminal elimination half-life for cortical retention is 56 days, reflecting prolonged renal tubular uptake.
Primarily renal; approximately 95% of administered activity is excreted in urine within 6 hours post-injection. Less than 5% is excreted in feces.
Renal: ~50% excreted unchanged in urine within 24 hours; remaining fraction retained in renal tubular cells with gradual release over weeks.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical